To view the webinar replay of “PRECISE-AD Phase 1b Blinded Interim Data Analysis"  Click Here

Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Latest News

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

View Press Release View All News
PRECISE-AD Interim Results Presentation

Latest Presentation

PRECISE-AD Interim Results Presentation

View Presentation View All Presentations

Upcoming Events

There are no upcoming events scheduled at this time. Sign up here to receive notices about upcoming events and press releases.

View All Events

Past Events

Alzheimer’s Association International Conference (AAIC)

BIO International Convention

View All Events

Latest Financial Results

Q1 2026

Quarter Ended Mar 31, 2026
Earnings Release
PDF HTML
10-Q Filing
PDF HTML
XBRL
ZIP HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2025

Report Links

Company Overview

ProMIS™ Neurosciences, Inc. (Nasdaq: PMN), is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company has offices in Toronto, Ontario, and Cambridge, Massachusetts.

View Management Team View Board of Directors

Toronto, Canada Office

Address

1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2
Canada

Cambridge, MA U.S. Office

Address

Cambridge Innovation Center
1 Broadway
Cambridge, MA 02142
U.S.A.